Holen Sie sich die Stockscreener-App
11.52
0.09%
-0.010
Handel nachbörslich:
11.52
Schlusskurs vom Vortag:
$11.53
Offen:
$11.55
24-Stunden-Volumen:
476.52K
Relative Volume:
0.55
Marktkapitalisierung:
$880.70M
Einnahmen:
$54.55M
Nettoeinkommen (Verlust:
$-193.57M
KGV:
-3.9862
EPS:
-2.89
Netto-Cashflow:
$-181.86M
1W Leistung:
+2.77%
1M Leistung:
-0.86%
6M Leistung:
-42.20%
1J Leistung:
-45.25%
1-Tages-Spanne:
$11.45
$11.70
1-Wochen-Bereich:
$11.13
$11.87
52-Wochen-Spanne:
$8.18
$29.56
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Firmenname
Nurix Therapeutics Inc
Sektor
Branche
Telefon
(415) 660-5320
Adresse
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Vergleichen Sie NRIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
11.52 | 881.46M | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-17 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-11 | Eingeleitet | Jefferies | Buy |
| 2024-09-06 | Fortgesetzt | Robert W. Baird | Outperform |
| 2024-07-31 | Eingeleitet | Truist | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-03-09 | Eingeleitet | Barclays | Overweight |
| 2023-02-28 | Eingeleitet | Oppenheimer | Outperform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-12-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-30 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-04-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-11-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-18 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-18 | Eingeleitet | Needham | Buy |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-18 | Eingeleitet | Stifel | Buy |
Alle ansehen
Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten
New York State Common Retirement Fund Has $626,000 Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Massachusetts Financial Services Co. MA Has $511,000 Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
What drives Nurix Therapeutics Inc. stock priceTremendous financial leverage - PrintWeekIndia
Nurix Therapeutics Inc. Stock Analysis and ForecastPhenomenal returns - PrintWeekIndia
Non-Hodgkin’s Lymphoma Market Forecast to Surge with Growing Adoption of Targeted and Cell-Based Therapies | DelveInsight - GlobeNewswire Inc.
Is Nurix Therapeutics Inc. a good long term investmentExceptional trading results - Autocar Professional
Hussman Strategic Advisors Inc. Takes Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Down 5.4%What's Next? - MarketBeat
Janux Therapeutics Receives Buy Rating from Leerink Partners Amid Strategic Initiatives and Long-Term Growth Potential - AInvest
What analysts say about Nurix Therapeutics Inc. stockUnmatched profit potential - jammulinksnews.com
Q3 EPS Forecast for Nurix Therapeutics Raised by Analyst - MarketBeat
Janux Therapeutics (JANX) Soars 2.31% on R&D Day Announcement - AInvest
Nurix Therapeutics’ SWOT analysis: biotech stock’s pivotal trials and pipeline progress By Investing.com - Investing.com South Africa
Nurix Therapeutics’ SWOT analysis: biotech stock’s pivotal trials and pipeline progress - Investing.com Australia
When (NRIX) Moves Investors should Listen - news.stocktradersdaily.com
Nurix Therapeutics price target lowered to $34 from $36 at H.C. Wainwright - Yahoo Finance
NRIX: Morgan Stanley Lowers Price Target for Nurix Therapeutics - GuruFocus
A Glimpse Into The Expert Outlook On Nurix Therapeutics Through 5 Analysts - Benzinga
Nurix Therapeutics (NASDAQ:NRIX) Price Target Lowered to $34.00 at HC Wainwright - MarketBeat
H.C. Wainwright Adjusts Price Target for Nurix Therapeutics (NRI - GuruFocus
Navigating Nurix Therapeutics' Early-Stage Biotech Landscape: A Strategic SWOT Analysis - AInvest
Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher - simplywall.st
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap Up on Better-Than-Expected Earnings - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Price Target Cut to $30.00 by Analysts at Oppenheimer - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Issues Earnings Results - MarketBeat
Nurix Therapeutics: The BTK Disruptor With Undervalued Upside Potential - AInvest
Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors (NASDAQ:NRIX) - Seeking Alpha
Nurix Therapeutics (NASDAQ:NRIX) Shares Up 7.8% After Earnings Beat - MarketBeat
Top 3 Trending Stocks: Ultragenyx Pharmaceutical, Rhythm Pharmaceuticals, and Nurix Therapeutics - AInvest
Stifel Nicolaus Keeps Their Buy Rating on Nurix Therapeutics (NRIX) - The Globe and Mail
Piper Sandler Keeps Their Buy Rating on Nurix Therapeutics (NRIX) - The Globe and Mail
Analysts’ Top Healthcare Picks: Nurix Therapeutics (NRIX), Abbott Laboratories (ABT) - The Globe and Mail
Finanzdaten der Nurix Therapeutics Inc-Aktie (NRIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):